{"count": 17, "results": [{"_id": "37348156", "pmid": 37348156, "pmcid": "PMC10363482", "title": "Metformin inhibits methylglyoxal-induced retinal pigment epithelial cell death and retinopathy via AMPK-dependent mechanisms: Reversing mitochondrial dysfunction and upregulating glyoxalase 1", "journal": "Redox Biol", "authors": ["Sekar P", "Hsiao G", "Hsu SH", "Huang DY", "Lin WW", "Chan CM"], "date": "2023-06-15T00:00:00Z", "doi": "10.1016/j.redox.2023.102786", "meta_date_publication": "2023 Jun 15", "meta_volume": "64", "meta_issue": "", "meta_pages": "102786", "score": 50269.75, "text_hl": "Although the therapeutic potential of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for @<m>DISEASE_Hypertensive_Retinopathy</m> @DISEASE_MESH:D058437 @@@retinopathy disorders@@@ has recently been elucidated, possibly through @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@ activation, it remains unknown how @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ directly affects the @CHEMICAL_Pyruvaldehyde @CHEMICAL_MESH:D011765 @@@MGO@@@-induced stress response in @DISEASE_Retinitis @DISEASE_MESH:D012173 @@@retinal pigment@@@ epithelial cells. ", "citations": {"NLM": "Sekar P, Hsiao G, Hsu SH, Huang DY, Lin WW, Chan CM. Metformin inhibits methylglyoxal-induced retinal pigment epithelial cell death and retinopathy via AMPK-dependent mechanisms: Reversing mitochondrial dysfunction and upregulating glyoxalase 1 Redox Biol. 2023 Jun 15;64():102786. PMID: 37348156", "BibTeX": "@article{37348156, title={Metformin inhibits methylglyoxal-induced retinal pigment epithelial cell death and retinopathy via AMPK-dependent mechanisms: Reversing mitochondrial dysfunction and upregulating glyoxalase 1}, author={Sekar P and Hsiao G and Hsu SH and Huang DY and Lin WW and Chan CM}, journal={Redox Biol}, volume={64}, pages={102786}}"}}, {"_id": "33133865", "pmid": 33133865, "pmcid": "PMC7594657", "title": "Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence", "journal": "Cureus", "authors": ["Sahay RK", "Mittal V", "Gopal GR", "Kota S", "Goyal G", "Abhyankar M", "Revenkar S"], "date": "2020-09-28T00:00:00Z", "doi": "10.7759/cureus.10700", "meta_date_publication": "2020 Sep 28", "meta_volume": "12", "meta_issue": "9", "meta_pages": "e10700", "score": 50250.93, "text_hl": "Strengths of @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@glimepiride@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ combinations Number of @SPECIES_9606 @@@patients@@@ (%)   1 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 0.5 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 500 mg 640 (13.17%)   2 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 0.5 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 1000 mg 175 (3.6%)   3 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 1 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 500 mg 1194 (24.57%)   4 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 1 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 850 mg 72 (1.48%)   5 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 1 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 1000 mg 393 (8.08%)   6 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 2 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 500 mg 1297 (26.69%)   7 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 2 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 1000 mg 528 (10.86%)   8 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 2 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 850 mg 232 (4.76%)   10 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 3 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 1000 mg 200 (4.11%)   11 @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@Glimepiride@@@ 4 mg and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ 1000 mg 127 (2.61%)   ", "citations": {"NLM": "Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G, Abhyankar M, Revenkar S. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence Cureus. 2020 Sep 28;12(9):e10700. PMID: 33133865", "BibTeX": "@article{33133865, title={Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence}, author={Sahay RK and Mittal V and Gopal GR and Kota S and Goyal G and Abhyankar M and Revenkar S}, journal={Cureus}, volume={12}, number={9}, pages={e10700}}"}}, {"_id": "32774367", "pmid": 32774367, "pmcid": "PMC7396103", "title": "Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes", "journal": "Int J Endocrinol", "authors": ["Chin SO", "Ha IG", "Rhee SY", "Jeong SJ", "Chon S", "Kim SH", "Ahn KJ", "Baik SH", "Park Y", "Nam MS", "Lee KW", "Woo JT"], "date": "2020-07-24T00:00:00Z", "doi": "10.1155/2020/9879517", "meta_date_publication": "2020", "meta_volume": "2020", "meta_issue": "", "meta_pages": "9879517", "score": 50248.387, "text_hl": "In particular, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ nonusers had higher prevalence of accompanying comorbidities including @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@cancers@@@ and @DISEASE_603933 @DISEASE_OMIM:603933 @@@microvascular complications@@@ such as @<m>DISEASE_Hypertensive_Retinopathy</m> @DISEASE_MESH:D058437 @@@retinopathy@@@, @DISEASE_Peripheral_Nervous_System_Diseases @DISEASE_MESH:D010523 @@@peripheral neuropathy@@@, and @DISEASE_Cataract @DISEASE_MESH:D002386 @@@cataracts@@@. ", "citations": {"NLM": "Chin SO, Ha IG, Rhee SY, Jeong SJ, Chon S, Kim SH, Ahn KJ, Baik SH, Park Y, Nam MS, Lee KW, Woo JT. Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes Int J Endocrinol. 2020;2020():9879517. PMID: 32774367", "BibTeX": "@article{32774367, title={Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes}, author={Chin SO and Ha IG and Rhee SY and Jeong SJ and Chon S and Kim SH and Ahn KJ and Baik SH and Park Y and Nam MS and Lee KW and Woo JT}, journal={Int J Endocrinol}, volume={2020}, pages={9879517}}"}}, {"_id": "32911202", "pmid": 32911202, "title": "Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus.", "journal": "Diabetes Metab Syndr", "authors": ["Kher M", "Beri S", "Rehan HS", "Prakash A", "Gupta LK"], "date": "2020-11-01T00:00:00Z", "doi": "10.1016/j.dsx.2020.08.016", "meta_date_publication": "2020 Nov-Dec", "meta_volume": "14", "meta_issue": "6", "meta_pages": "1703-1710", "score": 50247.715, "text_hl": ".@@@ METHODS: 60 @SPECIES_9606 @@@patients@@@ of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@ without @<m>DISEASE_Hypertensive_Retinopathy</m> @DISEASE_MESH:D058437 @@@retinopathy@@@ and 60 of @DISEASE_Diabetic_Retinopathy @DISEASE_MESH:D003930 @@@diabetic retinopathy@@@ were enrolled to receive @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (500 mg-1000 mg) combined with either @CHEMICAL_glimepiride @CHEMICAL_MESH:C057619 @@@glimepiride@@@ (1 mg-2 mg) or @GENE_INS @GENE_3630 @@@insulin@@@. ", "citations": {"NLM": "Kher M, Beri S, Rehan HS, Prakash A, Gupta LK. Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus. Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1703-1710. PMID: 32911202", "BibTeX": "@article{32911202, title={Effect of metformin and insulin combination on monocyte chemoattractant protein-1 and cathepsin-D in type 2 diabetes mellitus.}, author={Kher M and Beri S and Rehan HS and Prakash A and Gupta LK}, journal={Diabetes Metab Syndr}, volume={14}, number={6}, pages={1703-1710}}"}}, {"_id": "40446475", "pmid": 40446475, "title": "Chronic beta-carotene, magnesium, and zinc supplementation together with metformin attenuates diabetes-related complications in aged rats.", "journal": "Clin Nutr", "authors": ["Kateel R", "Kashyap NN", "Reddy SK", "Shetty S", "Kumari MK", "Ullal SD", "Holla SN", "Aroor A", "Hill MA", "Belle VS", "Prabhu K", "Joshi MB", "Upadhya D"], "date": "2025-07-01T00:00:00Z", "doi": "10.1016/j.clnu.2025.05.004", "meta_date_publication": "2025 Jul", "meta_volume": "50", "meta_issue": "", "meta_pages": "183-197", "score": 50243.656, "text_hl": "Mechanistically, the significant improvement in BMZ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in controlling @<m>DISEASE_Hypertensive_Retinopathy</m> @DISEASE_MESH:D058437 @@@retinopathy@@@, @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@nephropathy@@@, and @DISEASE_Nervous_System_Diseases @DISEASE_MESH:D009422 @@@neuropathy@@@ are directly linked to (1) Increased glycemic control (antihyperglycemic effect), (2) increased @GENE_INS @GENE_3630 @@@insulin@@@ sensitivity as evidenced by reduced HOMA-IR levels, (3) reduced oxidative stress (4) increased antioxidant activity through increased @CHEMICAL_Glutathione @CHEMICAL_MESH:D005978 @@@glutathione@@@ levels and increased GSH/GSSG ratio, and (5) improved regulation of @CHEMICAL_Carbohydrates @CHEMICAL_MESH:D002241 @@@carbohydrate@@@ and @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@ metabolism as evidenced by metabolomic data. ", "citations": {"NLM": "Kateel R, Kashyap NN, Reddy SK, Shetty S, Kumari MK, Ullal SD, Holla SN, Aroor A, Hill MA, Belle VS, Prabhu K, Joshi MB, Upadhya D. Chronic beta-carotene, magnesium, and zinc supplementation together with metformin attenuates diabetes-related complications in aged rats. Clin Nutr. 2025 Jul;50():183-197. PMID: 40446475", "BibTeX": "@article{40446475, title={Chronic beta-carotene, magnesium, and zinc supplementation together with metformin attenuates diabetes-related complications in aged rats.}, author={Kateel R and Kashyap NN and Reddy SK and Shetty S and Kumari MK and Ullal SD and Holla SN and Aroor A and Hill MA and Belle VS and Prabhu K and Joshi MB and Upadhya D}, journal={Clin Nutr}, volume={50}, pages={183-197}}"}}, {"_id": "40182582", "pmid": 40182582, "title": "The association between duration of metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis.", "journal": "J Diabetes Metab Disord", "authors": ["Bahardoust M", "Mehrabi Y", "Hadaegh F", "Azizi F", "Khalili D", "Delpisheh A"], "date": "2025-04-01T00:00:00Z", "doi": "10.1007/s40200-025-01577-w", "meta_date_publication": "2025 Jun", "meta_volume": "24", "meta_issue": "1", "meta_pages": "94", "score": 50241.527, "text_hl": "The incidence of @DISEASE_603933 @DISEASE_OMIM:603933 @@@microvascular complications@@@ (@DISEASE_Diabetic_Nephropathies @DISEASE_MESH:D003928 @@@diabetic nephropathy@@@ or @<m>DISEASE_Hypertensive_Retinopathy</m> @DISEASE_MESH:D058437 @@@retinopathy@@@) was defined as outcomes. ", "citations": {"NLM": "Bahardoust M, Mehrabi Y, Hadaegh F, Azizi F, Khalili D, Delpisheh A. The association between duration of metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis. J Diabetes Metab Disord. 2025 Jun;24(1):94. PMID: 40182582", "BibTeX": "@article{40182582, title={The association between duration of metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis.}, author={Bahardoust M and Mehrabi Y and Hadaegh F and Azizi F and Khalili D and Delpisheh A}, journal={J Diabetes Metab Disord}, volume={24}, number={1}, pages={94}}"}}, {"_id": "25785990", "pmid": 25785990, "pmcid": "PMC4364739", "title": "Anti-Angiogenic Effect of Metformin in Mouse Oxygen-Induced Retinopathy Is Mediated by Reducing Levels of the Vascular Endothelial Growth Factor Receptor Flk-1", "journal": "PLoS One", "authors": ["Joe SG", "Yoon YH", "Choi JA", "Koh JY"], "date": "2015-03-18T00:00:00Z", "doi": "10.1371/journal.pone.0119708", "meta_date_publication": "2015", "meta_volume": "10", "meta_issue": "3", "meta_pages": "e0119708", "score": 50058.758, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ inhibited normalization of @CHEMICAL_Oxygen @CHEMICAL_MESH:D010100 @@@oxygen@@@-induced @<m>DISEASE_Hypertensive_Retinopathy</m> @DISEASE_MESH:D058437 @@@retinopathy@@@", "citations": {"NLM": "Joe SG, Yoon YH, Choi JA, Koh JY. Anti-Angiogenic Effect of Metformin in Mouse Oxygen-Induced Retinopathy Is Mediated by Reducing Levels of the Vascular Endothelial Growth Factor Receptor Flk-1 PLoS One. 2015;10(3):e0119708. PMID: 25785990", "BibTeX": "@article{25785990, title={Anti-Angiogenic Effect of Metformin in Mouse Oxygen-Induced Retinopathy Is Mediated by Reducing Levels of the Vascular Endothelial Growth Factor Receptor Flk-1}, author={Joe SG and Yoon YH and Choi JA and Koh JY}, journal={PLoS One}, volume={10}, number={3}, pages={e0119708}}"}}, {"_id": "662185", "pmid": 662185, "title": "[Preliminary findings on 2 groups of diabetics with regard to platelet aggregation in relation to retinopathy and ultimate relation to antidiabetic therapy].", "journal": "Minerva Med", "authors": ["Cavaliere R", "Giangrandi E", "Innocenti M", "Parisi R"], "date": "1978-06-02T00:00:00Z", "meta_date_publication": "1978 Jun 2", "meta_volume": "69", "meta_issue": "28", "meta_pages": "1923-8", "score": 50055.05, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ normalised clumping in the course of mild @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@.", "citations": {"NLM": "Cavaliere R, Giangrandi E, Innocenti M, Parisi R. [Preliminary findings on 2 groups of diabetics with regard to platelet aggregation in relation to retinopathy and ultimate relation to antidiabetic therapy]. Minerva Med. 1978 Jun 2;69(28):1923-8. PMID: 662185", "BibTeX": "@article{662185, title={[Preliminary findings on 2 groups of diabetics with regard to platelet aggregation in relation to retinopathy and ultimate relation to antidiabetic therapy].}, author={Cavaliere R and Giangrandi E and Innocenti M and Parisi R}, journal={Minerva Med}, volume={69}, number={28}, pages={1923-8}}"}}, {"_id": "16153370", "pmid": 16153370, "title": "[Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis].", "journal": "Aten Primaria", "authors": ["Sáenz Calvo A", "Fernández Esteban I", "Mataix Sanjuán A", "Ausejo Segura M", "Roqué M", "Moher D"], "date": "2005-09-15T00:00:00Z", "doi": "10.1157/13078602", "meta_date_publication": "2005 Sep 15", "meta_volume": "36", "meta_issue": "4", "meta_pages": "183-91", "score": 50049.062, "text_hl": "[@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ for @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type-2 diabetes mellitus@@@. ", "citations": {"NLM": "Sáenz Calvo A, Fernández Esteban I, Mataix Sanjuán A, Ausejo Segura M, Roqué M, Moher D. [Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis]. Aten Primaria. 2005 Sep 15;36(4):183-91. PMID: 16153370", "BibTeX": "@article{16153370, title={[Metformin for type-2 diabetes mellitus. Systematic review and meta-analysis].}, author={Sáenz Calvo A and Fernández Esteban I and Mataix Sanjuán A and Ausejo Segura M and Roqué M and Moher D}, journal={Aten Primaria}, volume={36}, number={4}, pages={183-91}}"}}, {"_id": "16034881", "pmid": 16034881, "title": "Metformin monotherapy for type 2 diabetes mellitus.", "journal": "Cochrane Database Syst Rev", "authors": ["Saenz A", "Fernandez-Esteban I", "Mataix A", "Ausejo M", "Roque M", "Moher D"], "date": "2005-07-20T00:00:00Z", "doi": "10.1002/14651858.CD002966.pub3", "meta_date_publication": "2005 Jul 20", "meta_volume": "", "meta_issue": "3", "meta_pages": "CD002966", "score": 50048.83, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ monotherapy for @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@.", "citations": {"NLM": "Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. PMID: 16034881", "BibTeX": "@article{16034881, title={Metformin monotherapy for type 2 diabetes mellitus.}, author={Saenz A and Fernandez-Esteban I and Mataix A and Ausejo M and Roque M and Moher D}, journal={Cochrane Database Syst Rev}, number={3}, pages={CD002966}}"}}]}